GlobeNewswire·Nov 10, 2026, 7:30 AM ET

BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights

Revenue increased 34% to $18.1 million in Q3 2026
Operating income rose 107% to $2.6 million
Adjusted EBITDA increased approximately 92% to $3.9 million
Operating cash flow reached $6.2 million
Remaining performance obligations grew 31% year-over-year to approximately $85 million
Shipped 130 Deep TMS systems in Q3 2026, a 44% increase year-over-year
Total installed base reached approximately 2,080 systems
OCD coil sales increased 17% year-over-year to 54 coils
Total installed base of OCD coils is approximately 1,000
Net income increased 42% to $2.2 million
Cash, cash equivalents, short-term deposits, & restricted cash totaled $63.4 million as of September 30, 2026
Reported peer-reviewed data showing a 70% relative reduction in suicidal ideation after six weeks of Deep TMS treatment
Reported pilot data showing an 83.3% response rate & 50% remission rate for depression with comorbid early-stage Alzheimer's disease
Favorable SWIFT™ protocol coverage now extends to over 70 million covered lives in the U.S.
Made $3 million & $0.8 million follow-on MSO investments in Radial Health, Inc. & Heading Health, respectively
Entered a strategic collaboration with Inland Psychiatric Medical Group for multisystem Deep TMS orders
Full-year 2026 revenue, operating income margin, & Adjusted EBITDA expected at the upper end of guidance with potential to modestly exceed it